MPM BioVentures 2014, L.P. (EVNIN LUKE, GADICKE ANSBERT) sold $1.9M of TRDA (indirect holdings)
MPM BioVentures 2014, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, which may be interpreted as a bearish signal for the stock.
Market read
Primary insider sale of a micro‑cap biotech; modest impact on price and sentiment.
What to watch
Potential upcoming clinical data or financing needs not disclosed in the filing.
Background
Form 4 filings disclose insider transactions; they are primary sources for regulatory reporting.
Ticker impact
SEC Form 4 shows MPM BioVentures sold ~1.9M shares of Entrada Therapeutics at $7.11‑$7.41, reducing its stake to 3.9M shares.
Potential short‑term dip of 2‑4% as market digests the sell‑off.
The transaction is a primary disclosure but the dollar amount is small; insider sales often weigh on sentiment for low‑float stocks.
Market effects
Minimal; biotech sector unlikely to move on a single insider sale.
None; the filing is U.S.‑based and affects only Entrada Therapeutics.
Low; no broader market effect.
Counterpoint
The sale could be a routine liquidity move unrelated to fundamentals; price may hold.
Key entities
- CompanyEntrada Therapeutics, Inc.
Biopharmaceutical company developing therapies; ticker TRDA.
- InvestorMPM BioVentures 2014, L.P.
Private investment vehicle holding a 10% stake in Entrada.
